Precigen Appoints New CEO, Dr. Helen Torley
Ticker: PGEN · Form: 8-K · Filed: Sep 23, 2024 · CIK: 1356090
| Field | Detail |
|---|---|
| Company | Precigen, Inc. (PGEN) |
| Form Type | 8-K |
| Filed Date | Sep 23, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, executive-appointment, ceo
Related Tickers: HALO
TL;DR
Precigen gets a new CEO, Dr. Helen Torley, from Halozyme. Big pharma experience incoming.
AI Summary
Precigen, Inc. announced on September 20, 2024, the appointment of Dr. Helen B. Torley as its new Chief Executive Officer, effective immediately. Dr. Torley, who previously served as President and CEO of Halozyme Therapeutics, will also join the company's Board of Directors. This leadership change follows the departure of former CEO, Dr. Alan D. Sauer.
Why It Matters
The appointment of a new CEO with a strong background in the biopharmaceutical industry could signal a strategic shift or renewed focus for Precigen, potentially impacting its future development and market performance.
Risk Assessment
Risk Level: medium — Leadership changes can introduce uncertainty regarding strategic direction and operational execution, impacting investor confidence.
Key Players & Entities
- Precigen, Inc. (company) — Registrant
- Dr. Helen B. Torley (person) — Newly appointed Chief Executive Officer and Board Member
- Dr. Alan D. Sauer (person) — Former Chief Executive Officer
- Halozyme Therapeutics (company) — Previous employer of Dr. Torley
- September 20, 2024 (date) — Effective date of appointment
FAQ
Who has been appointed as the new CEO of Precigen, Inc.?
Dr. Helen B. Torley has been appointed as the new Chief Executive Officer of Precigen, Inc.
When was the appointment of the new CEO effective?
The appointment of Dr. Helen B. Torley as CEO was effective September 20, 2024.
What other role will Dr. Helen B. Torley assume at Precigen?
Dr. Helen B. Torley will also join the Board of Directors of Precigen, Inc.
Who did Dr. Helen B. Torley previously work for?
Dr. Helen B. Torley previously served as President and CEO of Halozyme Therapeutics.
Who is the former CEO of Precigen, Inc.?
Dr. Alan D. Sauer is the former CEO of Precigen, Inc.
Filing Stats: 473 words · 2 min read · ~2 pages · Grade level 11.2 · Accepted 2024-09-20 19:44:21
Filing Documents
- dp218268_8k.htm (8-K) — 22KB
- 0000950103-24-013816.txt ( ) — 189KB
- pgen-20240920.xsd (EX-101.SCH) — 3KB
- pgen-20240920_lab.xml (EX-101.LAB) — 33KB
- pgen-20240920_pre.xml (EX-101.PRE) — 22KB
- dp218268_8k_htm.xml (XML) — 3KB
02
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 23, 2024, Precigen, Inc. (the "Company") announced the separation from employment of Jeffrey Perez, Senior Vice President, Intellectual Property Affairs, effective November 1, 2024. Mr. Perez is expected to remain in his current position through his separation date in order to facilitate a smooth transition of his duties. In connection with his departure, it is expected that Mr. Perez will receive the severance payments and benefits provided under his continuing employment agreement with the Company, dated April 2, 2019, the terms of which are described in the Company's 2024 Proxy Statement filed with the Securities and Exchange Commission on May 28, 2024. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Precigen, Inc. By: /s/ Donald P. Lehr Donald P. Lehr Chief Legal Officer Dated: September 20, 2024